||Recombinant Human XIAP (Accession # AAC50373) was produced in E. coli-derived.
|Predicted N Terminal:
||Supplied as a 0.2 µm filtered solution in HEPES, NaCl, DTT and Glycerol.
||Measured by its ability to inhibit DEVD-AFC cleavage activity by Recombinant Human Caspase-7 .The IC50 for inhibition of rhCaspase-7 activity is <50 nM, as measured under the described conditions.
||Recombinant Human XIAP has a calculated MW of 58 kDa. In SDS-PAGE migrates as 54-56 kDa, reducing conditions.
||>85%, by SDS-PAGE under reducing conditions and visualized by silver stain.
||Avoid repeated freeze-thaw cycles. No activity loss was observed after storage at: In lyophilized state for 1 year (4ºC); After reconstitution under sterile conditions for 3 months (-70ºC).